Femasys Has Activated Enrollment For Its Pivotal FemBloc Trial At Its First Academic Site In Brooklyn, New York, To Investigate The Safety And Efficacy Of Its Investigational Permanent Birth Control Candidate
Portfolio Pulse from Benzinga Newsdesk
Femasys has activated enrollment for its pivotal FemBloc trial at its first academic site in Brooklyn, New York. The trial will investigate the safety and efficacy of its investigational permanent birth control candidate.
September 27, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Femasys has started enrollment for its FemBloc trial, which could potentially impact the company's stock depending on the trial results.
The initiation of the FemBloc trial by Femasys is a significant event for the company. The results of the trial could potentially have a significant impact on the company's stock. If the trial results are positive, it could lead to increased investor confidence and a potential rise in the stock price. Conversely, if the trial results are negative, it could lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100